Lymphatic Vasculature and Hair Follicle Regeneration

    Anna Cazzola, Mirna Perez-Moreno
    TLDR Lymphatic vessels help hair follicles regenerate by interacting with stem cells.
    The document explores the active role of lymphatic vessels (LV) in hair follicle (HF) regeneration, beyond their traditional function of fluid drainage. It highlights the interaction between LVs, hair follicle stem cells (HFSC), and the dermal papilla (DP), which influences HF growth and regeneration. HFSCs recruit LVs to their niche, with LVs surrounding the HF bulge and connecting neighboring HFs. The regulation of LVs by HFSCs varies with the HF stage, affecting LV flow and tissue drainage. Gene expression changes in HFSCs and LVs are linked to LV reorganization, driven by HFSC-secreted proteins. This study suggests a complex crosstalk between LVs and HFSCs, with potential implications for regenerative therapies and disease treatment, although further research is needed to fully understand this interaction.
    Discuss this study in the Community →

    Research cited in this study

    25 / 25 results

    Related Community Posts Join

    6 / 6 results

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  44 upvotes 4 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community 4 months on 2.5 mg OM, no improvement

      in Minoxidil  6 upvotes 1 year ago
      After 4 months on oral minoxidil with no significant hair regrowth, a user is frustrated and considering alternative treatments since they can't take finasteride due to side effects. Suggestions include natural DHT blockers, lifestyle changes, and other hair care tips.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  40 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

    Related Research

    1 / 1 results